Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

State Surgeon General Dr. Joseph Ladapo is speaking to the community about the updated federal recommendations for healthy ...

COVID-19 cases are rising in half of U.S. states. What to know about COVID trends and the new Stratus and Nimbus variants.

Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in ...

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

CSIR-Centre for Cellular and Molecular Biology (CCMB) Atal Incubation Centre (AIC) is planning to go ahead with the next stage larger-scale trials of the indigenously developed mRNA vaccine technology ...

As vaccination rates among children continue to plummet, concerns are rising over the potential for infectious disease to spread rampantly.

It's difficult to get motivated about buying a stock that's plummeted or a company that seems to be out of favor with the ...

Moderna’s COVID-19 vaccine has received full FDA approval for use in children at higher risk for severe illness.

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...